CSPIA
MRNA icon

Cary Street Partners Investment Advisory’s Moderna MRNA Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,990
Closed -$236K – 776
2024
Q2 		$236K Buy
+1,990
New +$252K 0.01% 664
2023
Q4 		– Sell
-1,184
Closed -$122K – 1360
2023
Q3 		$122K Buy
1,184
+30
+3% +$3.35K 0.01% 657
2023
Q2 		$140K Buy
1,154
+83
+8% +$11.1K 0.01% 596
2023
Q1 		$164K Buy
1,071
+165
+18% +$27.2K 0.01% 508
2022
Q4 		$163K Buy
+906
New +$148K 0.01% 502
2022
Q3 		– Sell
-914
Closed -$131K – 540
2022
Q2 		$131K Buy
+914
New +$131K 0.01% 481
2021
Q3 		– Sell
-242
Closed -$57K – 286
2021
Q2 		$57K Buy
242
+107
+79% +$19.1K 0.02% 283
2021
Q1 		$18K Buy
+135
New +$19.6K 0.01% 297

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cary Street Partners Investment Advisory's MRNA Position: Q3 2024 in Review

Cary Street Partners Investment Advisory sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,990 shares — an estimated $236K sold.

Cary Street Partners Investment Advisory first reported a position in MRNA in Q1 2021 and held it in 8 quarters. The position peaked at $236K in Q2 2024. 789 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Cary Street Partners Investment Advisory reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 1,990 Moderna shares in Q3 2024, an estimated $236K.
  • Cary Street Partners Investment Advisory first reported a position in Moderna in Q1 2021 and held it in 8 quarters.
  • Cary Street Partners Investment Advisory's Moderna position peaked at $236K in Q2 2024.
  • 789 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Cary Street Partners Investment Advisory's 13F filing for Q3 2024, filed 30 Oct 2024.